Skip to main content
Thermo Fisher announces completion of $7.2B Patheon purchase

Thermo Fisher Scientific finalized the $7.2 billion acquisition of 95.3% in ordinary shares of Patheon, a contract development and manufacturing organization that provides drug development services and delivery solutions. The purchase will enhance Thermo Fisher's CDMO capabilities in the fields of bioproduction technology and clinical trial services, said Marc Casper, Thermo Fisher's president and CEO.

Full Story: